How many insider trades does FilingIQ track for TSNDF?

FilingIQ tracks 71 Form 4 insider transactions for TSNDF (TerrAscend Corp.), covering filings from Mar 21, 2022 onwards. 10 of those were filed in the last 90 days.

Are TSNDF insiders net buyers or net sellers?

Across the full Form 4 history for TSNDF, 21 transactions (30%) were open-market purchases and 4 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TSNDF insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TSNDF in?

TerrAscend Corp. (TSNDF) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $249.73M.

TSNDF insider trading

OTC Markets OTCQX Healthcare

TerrAscend Corp. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

30% / 6%

Market cap

$249.73M

About TerrAscend Corp.

TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies. The company also operates retail dispensaries under the Apothecarium brand name. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

Company website: www.terrascend.com

TSNDF insider activity at a glance

FilingIQ has scored 71 insider transactions for TSNDF since Mar 21, 2022. The most recent filing in our index is dated Apr 27, 2026.

Across the full history, 21 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TSNDF insider trades is 41.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TSNDF trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for TSNDF?: FilingIQ tracks 71 Form 4 insider transactions for TSNDF (TerrAscend Corp.), covering filings from Mar 21, 2022 onwards. 10 of those were filed in the last 90 days.
Are TSNDF insiders net buyers or net sellers?: Across the full Form 4 history for TSNDF, 21 transactions (30%) were open-market purchases and 4 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TSNDF insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TSNDF in?: TerrAscend Corp. (TSNDF) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $249.73M.

Methodology & sources

Every TSNDF insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.